Skip to Content

Novacyt SA NYZ

Morningstar Rating
€0.81 +0.02 (2.79%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NYZ is trading at a 59% discount.
Price
€0.81
Fair Value
€3.46
Uncertainty
Extreme
1-Star Price
€23.51
5-Star Price
€8.32
Economic Moat
Fxyp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NYZ is a good fit for your portfolio.

Trading Information

Previous Close Price
€0.79
Day Range
€0.770.81
52-Week Range
€0.0413.78
Bid/Ask
€0.00 / €0.00
Market Cap
€57.28 Mil
Volume/Avg
0 /

Key Statistics

Price/Earnings (Normalized)
Price/Sales
6.50
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.06%

Company Profile

Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Value
Total Number of Employees
222

Valuation

Metric
NYZ
Price/Earnings (Normalized)
Price/Book Value
0.47
Price/Sales
6.50
Price/Cash Flow
Price/Earnings
NYZ

Financial Strength

Metric
NYZ
Quick Ratio
4.91
Current Ratio
5.09
Interest Coverage
−48.12
Quick Ratio
NYZ

Profitability

Metric
NYZ
Return on Assets (Normalized)
−12.04%
Return on Equity (Normalized)
−14.88%
Return on Invested Capital (Normalized)
−15.54%
Return on Assets
NYZ
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ABT
Abbott LaboratoriesKhcxtxdCzhthf$185.4 Bil
SYK
Stryker CorpMjcxyhphwxQpzd$127.7 Bil
BSX
Boston Scientific CorpFjxrvxpfvDqqvnq$107.6 Bil
MDT
Medtronic PLCXvgpngtvmRtqxwj$105.9 Bil
DXCM
DexCom IncVdljqljdwHwc$54.7 Bil
EW
Edwards Lifesciences CorpJpdmmpvgjGgnhcp$52.0 Bil
ZBH
Zimmer Biomet Holdings IncXdxxcpcrgRfdt$24.6 Bil
ALGN
Align Technology IncFrpmlxjqmSfnzc$23.4 Bil
PHG
Koninklijke Philips NV ADRTlgmmyyQmxvcw$18.7 Bil
PODD
Insulet CorpDvdfylsddDdnjbgr$11.6 Bil

Sponsor Center